Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe

Fig. 1

DCZ3301 treatment countered BTZ resistance and exhibited potent cytotoxicity against BTZ-resistant MM cells. (a) Molecular structure of DCZ3301. (b) The process of establishing BTZ-resistant cell lines. (c) Both BTZ-sensitive and BTZ-resistant MM cells treated with BTZ for 48 h and cell viability determined by CCK-8 assay. (d) CCK-8 assay demonstrated that DCZ3301 inhibited the viability of BTZ-resistant MM cells. (e) Soft agar colony formation by NCI-H929R and RPMI-8226R5 cells after DCZ3301 treatment. Representative images of colonies are shown in the left panel. Quantification of the colony numbers is presented in the right panel. (f) The effect of DCZ3301 on BTZ-resistant MM cell proliferation was evaluated by EdU incorporation assay. Scale bars = 100 μm.* p < 0.05 compared to control group. Data are presented as mean ± SD

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us